{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:34:22Z","timestamp":1772120062277,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Kyowa Hakko Kirin Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40261-018-0687-4","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T08:49:07Z","timestamp":1535618947000},"page":"945-954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study"],"prefix":"10.1007","volume":"38","author":[{"name":"Evocalcet Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanari","family":"Shiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"issue":"6","key":"687_CR1","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1053\/j.ajkd.2011.08.009","volume":"58","author":"RN Moorthi","year":"2011","unstructured":"Moorthi RN, Moe SM. CKD\u2013mineral and bone disorder: core curriculum 2011. Am J Kidney Dis. 2011;58(6):1022\u201336.","journal-title":"Am J Kidney Dis"},{"key":"687_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"key":"687_CR3","first-page":"923","volume":"18","author":"Y Nabeshima","year":"2008","unstructured":"Nabeshima Y. Clinical discovery of alpha-Klotho and FGF-23 unveiled new insight into calcium and phosphate homeostasis. Calcium. 2008;18:923\u201334.","journal-title":"Calcium"},{"issue":"4","key":"687_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1053\/j.ackd.2016.03.008","volume":"23","author":"ML Melamed","year":"2016","unstructured":"Melamed ML, Buttar RS, Coco M. CKD\u2013mineral bone disorder in stage 4 and 5 CKD: what we know today? Adv Chronic Kidney Dis. 2016;23(4):262\u20139.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"687_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/ckj\/sfv145","volume":"9","author":"G Cianciolo","year":"2016","unstructured":"Cianciolo G, Capelli I, Cappuccilli M, et al. Calcifying circulating cells: an uncharted area in the setting of vascular calcification in\u00a0CKD\u00a0patients. Clin Kidney J. 2016;9(2):280\u20136.","journal-title":"Clin Kidney J"},{"issue":"5","key":"687_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.nefro.2017.02.006","volume":"37","author":"M Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez M, Morales E, Gutierrez E, et al. Calciphylaxis: beyond CKD\u2013MBD. Nefrologia. 2017;37(5):501\u20137.","journal-title":"Nefrologia."},{"key":"687_CR7","doi-asserted-by":"publisher","first-page":"184321","DOI":"10.1155\/2015\/184321","volume":"2015","author":"E Hedgeman","year":"2015","unstructured":"Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. 2015;2015:184321.","journal-title":"Int J Nephrol"},{"key":"687_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/IJNRD.S4368","volume":"1","author":"JB Wetmore","year":"2008","unstructured":"Wetmore JB, Quarles LD. Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs. Int J Nephrol Renovasc Dis. 2008;1:5\u201317.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"5","key":"687_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1053\/j.ajkd.2016.05.015","volume":"68","author":"SC Palmer","year":"2016","unstructured":"Palmer SC, Gardner S, Tonelli M, et al. Phosphate-binding agents in adults with CKD: a network meta-analysis of randomized trials. Am J Kidney Dis. 2016;68(5):691\u2013702.","journal-title":"Am J Kidney Dis"},{"key":"687_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1525-139X.2011.00935.x","volume":"24","author":"JR Stubbs","year":"2011","unstructured":"Stubbs JR, Wetmore JB. Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? Semin Dial. 2011;24:298\u2013306.","journal-title":"Semin Dial"},{"issue":"5","key":"687_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/kisup.2013.90","volume":"3","author":"TB Dr\u00fceke","year":"2013","unstructured":"Dr\u00fceke TB. Calcimimetics and outcomes in CKD. Kidney Int Suppl. 2013;3(5):431\u20135.","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"687_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.jrn.2006.04.010","volume":"16","author":"PU Torres","year":"2006","unstructured":"Torres PU. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr. 2006;16(3):253\u20138.","journal-title":"J Ren Nutr"},{"issue":"4","key":"687_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of\u00a0cinacalcet\u00a0plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transpl. 2011;26(4):1327\u201339.","journal-title":"Nephrol Dial Transpl"},{"key":"687_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/ndt\/gfs356","volume":"28","author":"PA Ure\u00f1a-Torres","year":"2013","unstructured":"Ure\u00f1a-Torres PA, Floege J, Hawley CM, et al. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transpl. 2013;28:146\u201352.","journal-title":"Nephrol Dial Transpl"},{"key":"687_CR15","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"GM Chertow","year":"2012","unstructured":"Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482\u201394.","journal-title":"N Engl J Med"},{"issue":"9","key":"687_CR16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2215\/CJN.13081211","volume":"7","author":"M Fukagawa","year":"2012","unstructured":"Fukagawa M, Fukuma S, Onishi Y, et al. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol. 2012;7(9):1473\u201380.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"687_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2217\/fca.11.82","volume":"8","author":"C Karohl","year":"2012","unstructured":"Karohl C, Raggi P. Cinacalcet: will it play a role in reducing cardiovascular events? Future Cardiol. 2012;8(3):357\u201370.","journal-title":"Future Cardiol"},{"key":"687_CR18","doi-asserted-by":"publisher","first-page":"19612","DOI":"10.1038\/srep19612","volume":"6","author":"T Akizawa","year":"2016","unstructured":"Akizawa T, Kurita N, Mizobuchi M, et al. PTH-dependence of the effectiveness of\u00a0cinacalcet\u00a0in hemodialysis patients with secondary hyperparathyroidism. Sci Rep. 2016;6:19612.","journal-title":"Sci Rep"},{"issue":"5","key":"687_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","volume":"48","author":"D Padhi","year":"2009","unstructured":"Padhi D, Harris R. Clinical pharmacokinetic and pharmacodynamic profile of\u00a0cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303\u201311.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"687_CR20","doi-asserted-by":"publisher","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","volume":"13","author":"T Kawata","year":"2018","unstructured":"Kawata T, Tokunaga S, Murai M, et al. A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One. 2018;13(4):e0195316.","journal-title":"PLoS One"},{"issue":"2","key":"687_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.clinthera.2015.12.015","volume":"38","author":"H Liu","year":"2016","unstructured":"Liu H, Wang H, Liu T, Jiang J, Chen X, Gao F, Hu P. Pharmacokinetic and pharmacodynamic properties of\u00a0cinacalcet\u00a0(KRN1493) in Chinese healthy volunteers: a randomized, open-label, single ascending-dose and multiple-dose, parallel-group study. Clin Ther. 2016;38(2):348\u201357.","journal-title":"Clin Ther"},{"issue":"2","key":"687_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/00003495-200565020-00007","volume":"65","author":"JA Barman Balfour","year":"2005","unstructured":"Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs. 2005;65(2):271\u201381.","journal-title":"Drugs"},{"key":"687_CR23","first-page":"953","volume":"35","author":"J Azuma","year":"2007","unstructured":"Azuma J, Furuya Y, Uchida E. Phase I study of KRN1493 (cinacalcet hydrochloride) in healthy male volunteers-pharmacokinetics, pharmacodynamics and safety after single oral dosing. Jpn Pharmacol Ther. 2007;35:953\u201362.","journal-title":"Jpn Pharmacol Ther"},{"issue":"12","key":"687_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/j.1365-2362.2007.01874.x","volume":"37","author":"RP W\u00fcthrich","year":"2007","unstructured":"W\u00fcthrich RP, Martin D. Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Investig. 2007;37(12):915\u201322.","journal-title":"Eur J Clin Investig"},{"issue":"2","key":"687_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2165\/00002018-200528020-00003","volume":"28","author":"RR Shah","year":"2005","unstructured":"Shah RR. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf. 2005;28(2):115\u201325.","journal-title":"Drug Saf"},{"issue":"48","key":"687_CR26","first-page":"1966","volume":"70","author":"CS So","year":"1975","unstructured":"So CS, Batrice L, Volger E. Electrocardiographic changes in electrolyte inbalance. Part 2: alterations in\u00a0serum\u00a0calcium (author\u2019s transl). Med Klin. 1975;70(48):1966\u20138.","journal-title":"Med Klin"},{"key":"687_CR27","doi-asserted-by":"publisher","DOI":"10.5152\/anatoljcardiol.2015.6284","author":"G Temiz","year":"2015","unstructured":"Temiz G, Yal\u00e7\u0131n AU, Mutluay R, Bozac\u0131 \u0130, Bal C. Effects of cinacalcet treatment on QT interval in hemodialysis patients. Anatol J Cardiol. 2015. https:\/\/doi.org\/10.5152\/anatoljcardiol.2015.6284.","journal-title":"Anatol J Cardiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0687-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0687-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T11:29:12Z","timestamp":1616498952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0687-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0687-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738485526.793577516","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"assertion":[{"value":"30 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"TA has received consulting fees from Kyowa Hakko Kirin Co. Ltd., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Fuso Pharmaceutical Industries, Ltd., Japan Tobacco Inc., Ono Pharmaceutical Co. Ltd. and NIPRO Industry, and lecture fees from Kyowa Hakko Kirin Co. Ltd., Chugai Pharmaceutical Co. Ltd., Bayer Yakuhin, Ltd., Kissei Pharmaceutical Co. Ltd., Torii Pharmaceutical Co. Ltd. and Ono Pharmaceutical Co. Ltd. MF has received consulting fees from Kyowa Hakko Kirin Co. Ltd. and Ono Pharmaceutical Co. Ltd.; lecture fees from Kyowa Hakko Kirin Co. Ltd., Bayer Yakuhin, Ltd., Torii Pharmaceutical Co. Ltd. and Ono Pharmaceutical Co. Ltd.; and grants from Kyowa Hakko Kirin Co. Ltd. and Bayer Yakuhin, Ltd. MS has no conflicts of interest to declare. RS is employed by Kyowa Hakko Kirin Co. Ltd., which funded this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Prior to the start of the single-dose and multiple-dose studies, the study protocols were approved by the Hakata Clinic Institutional Review Board. The study was conducted in compliance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice Guidelines, the Declaration of Helsinki, and local laws.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was sponsored by Kyowa Hakko Kirin Co. Ltd. Medical writing and editorial support was funded by Kyowa Hakko Kirin Co. Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All subjects provided written informed consent. The study was conducted at the Hakata Clinic, Fukuoka, Japan.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}